Prolonged survival in a Patient with Chronic Myeloid Leukemia

Authors

  • Ashutosh Shukla Assitant Professor, Department of Medicine, B.P. Koirala Institute of Health Sciences, Dharan
  • O P Kalra MD, NMAMS, DM, FICP, Professor & Head, Department of Medicine, B.P. Koirala Institute of Health Sciences, Dharan

DOI:

https://doi.org/10.31729/jnma.694

Abstract

Patients with chronic myeloid leukemia treated with intermittent busulphan therapy have
an average survival rate of 2 to 4 years. The authors report here a patient who continues to
survive beyond one decade on busulphan therapy.

Downloads

How to Cite

Shukla, A., & Kalra, O. P. (2013). Prolonged survival in a Patient with Chronic Myeloid Leukemia. Journal of Nepal Medical Association, 39(133), 180–181. https://doi.org/10.31729/jnma.694

Issue

Vol. 39 No. 133 (2000)

Section

Case Reports

License

JNMA allow to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose. The author(s) are allowed to retain publishing rights without restrictions. The JNMA work is licensed under a Creative Commons Attribution 4.0 International License. More about Copyright Policy.

Most read articles by the same author(s)